Dyadic Logo Current.jpg
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
November 20, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
FFF Enterprises Inc.
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
September 13, 2023 13:34 ET | FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Alcatraz AI Appoints Moderna’s Dean Geribo to Advisory Board
May 16, 2023 09:00 ET | Alcatraz AI
CUPERTINO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Alcatraz AI, a global leader in autonomous access control solutions, today announced the appointment of Dean Geribo, Vice President, Corporate...
Moderna exercises option to license proprietary targeting technology from Autolus
October 12, 2022 07:00 ET | Autolus Therapeutics plc
- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus...
Dyadic Logo Current.jpg
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
August 10, 2022 16:00 ET | Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Dyadic Logo Current.jpg
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET | Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Dyadic Logo Current.jpg
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
April 13, 2022 08:52 ET | Dyadic International, Inc.
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s...
FXCM Group.png
FXCM January Single Share & Stock Baskets Report
March 02, 2022 04:00 ET | FXCM Group
SYDNEY, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- FXCM Group, LLC (“FXCM Group” or ‘FXCM’), the leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies...
FXCM January Single Share & Stock Baskets Report
March 02, 2022 04:00 ET | FXCM Group
LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- FXCM Group, LLC (“FXCM Group’ or ‘FXCM’), the leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies and related...
Arbutus Biopharma Logo
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
February 28, 2022 06:02 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...